Loading
Lung Cancer Research Studies / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Circulation Research · August 12, 2026
Encouraging direction, but not yet definitive.
This preclinical study identifies ERRα downregulation as a causal early event in anthracycline-induced cardiotoxicity and demonstrates that formononetin, a natural ERRα agonist, protects cardiac function in animal models via metabolic restoration while retaining anticancer activity in human-derived organoids. The work establishes proof-of-concept and direct target engagement but provides no evidence of clinical efficacy or safety in human patients receiving chemotherapy.
Preclinical mechanistic study: temporal protein analysis in porcine model, cardiomyocyte gain-of-function and loss-of-function transgenic mice, biochemical and molecular studies, human cancer organoid validation. Porcine cardiac tissue; cardiomyocyte-specific transgenic mice; cardiac tissue from chemotherapy-treated human patients (for comparison); human breast cancer patient-derived organoids. Intervention: Formononetin (natural ERRα agonist); cardiomyocyte-specific ERRα overexpression (gain-of-function transgenic). Compared with: Cardiomyocyte-specific ERRα knockdown (loss-of-function); doxorubicin alone; vehicle control.
ERRα expression selectively downregulated in anthracycline-treated pig hearts and cardiac tissue from chemotherapy-treated patients Cardiomyocyte-specific ERRα overexpression preserved systolic function after doxorubicin challenge in mice ERRα knockdown exacerbated bioenergetic failure and cardiac dysfunction in cardiomyocytes
No in vivo pharmacokinetics, dosing, or safety data in animal models
This work provides a mechanistic rationale and preclinical evidence for formononetin as a potential cardioprotective agent during anthracycline therapy. However, clinical translation requires human trials demonstrating safety and efficacy in reducing cardiotoxicity while preserving anticancer activity.
Sound mechanistic and preclinical work demonstrating a novel ERRα activator protects against anthracycline cardiotoxicity in animal models with direct target engagement, but lacks clinical trial data in human patients.
As stated by the source record.
Quoted from the source exactly as published.
This work provides a mechanistic rationale and preclinical evidence for formononetin as a potential cardioprotective agent during anthracycline therapy. However, clinical translation requires human trials demonstrating safety and efficacy in reducing cardiotoxicity while preserving anticancer activity.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Anthracycline-induced cardiotoxicity (AIC) limits life-saving chemotherapy and is driven by early metabolic remodeling. The nuclear receptor ERRα (estrogen-related receptor α) is a master regulator of cardiac energy metabolism, but the temporal dynamics of its downregulation, its causal role in AIC pathogenesis, and whether it can be pharmacologically activated to confer protection remain undefined. METHODS: We performed temporal protein analysis in a porcine AIC model. Using cardiomyocyte-specificgain- and loss-of-function mouse models, we assessed the causal role of ERRα. Mechanistic studies included ChIP-qPCR, reporter assays, and microscale thermophoresis to investigate the natural compound formononetin. Human breast cancer patient-derived organoids were used to evaluate anticancer activity. RESULTS: ERRα expression was selectively downregulated in AIC pig hearts and cardiac tissue from chemotherapy-treated patients. Temporal analysis in pigs revealed that ERRα reduction occurred at the subclinical (6-week) stage, preceding overt cardiac dysfunction. Cardiomyocyte-specific ERRα overexpression activated mitochondrial gene programs, enhanced fatty acid oxidation, and preserved systolic function after doxorubicin challenge, whereas ERRα knockdown exacerbated bioenergetic failure and cardiac dysfunction. Through drug screening, we identified formononetin as a potent and selective ERRα agonist. Formononetin enhanced ERRα transcriptional activity, improved mitochondrial metabolism, and protected against AIC in both murine and porcine models. Mechanistically, ChIP-qPCR demonstrated increased ERRα occupancy at target gene promoters, and microscale thermophoresis confirmed direct binding of formononetin to the ERRα/PGC-1α complex, indicating allosteric stabilization. Finally, in human breast cancer patient-derived organoids, formononetin alone reduced viability and proliferation, and combined with doxorubicin further enhanced antitumor efficacy. CONCLUSIONS: ERRα downregulation is a causal early event in the pathogenesis of AIC. Formononetin acts as a first-in-class selective ERRα activator that improves cardiac metabolism and function while retaining anticancer activity, supporting its potential as a dual-action cardioprotective agent during anthracycline therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.